Pharmaceutical company · JNJ

Johnson & Johnson
clinical trial
pipeline

Registry checked

Published

Guselkumab is linked to 18 distinct active studies, with 2 Phase 2, 12 Phase 3, 3 Phase 4, 1 without a recorded phase. Nipocalimab is linked to 12 distinct active studies, with 1 Phase 1, 1 Phase 2, 10 Phase 3. Amivantamab is linked to 13 distinct active studies, with 1 Phase 1, 7 Phase 2, 5 Phase 3.

Phase 2 study NCT07230860 in Dermatitis, Atopic lists estimated primary completion on 19 November 2026. Phase 3 study NCT03767244 in Prostatic Neoplasms lists estimated primary completion on 1 December 2026. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

266active trials
as lead sponsor
  • Phase 145
  • Phase 246
  • Phase 394
  • Phase 44
  • Phase not recorded77

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

2015 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

03Primary completion

Primary completion moved later by 192 days

2026-12-04 (estimated)2027-06-14 (estimated)
04 Dec 202614 Jun 2027

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157 · ClinicalTrials.gov
Recorded by ComplyRx
27 Oct 2026
Registry last updated
26 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020001122
2026-10-030000332
2026-10-041000011
2026-10-050000000
2026-10-060000000
2026-10-070000111
2026-10-080000111
2026-10-090000000
2026-10-100010121
2026-10-110000000
2026-10-120000000
2026-10-131000011
2026-10-140000111
2026-10-150000111
2026-10-160000000
2026-10-170000000
2026-10-180000221
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000221
2026-10-250000000
2026-10-260000000
2026-10-271110032
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals3121132015 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Guselkumab

Tremfya

18
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 22
  • Phase 312
  • Phase 43
  • Phase not recorded1
Studied condition
Arthritis, Juvenile · Arthritis, Psoriatic · Colitis, Ulcerative
Next primary completion
10 February 2027 · estimated
Open drug

Amivantamab

rybrevant

13
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 27
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Advanced or Metastatic Colorectal Cancer · Carcinoma, Non-small-Cell Lung · Carcinoma, Non-Small-Cell Lung
Next primary completion
27 April 2027 · estimated
Open drug

Nipocalimab

imaavy

12
Active trials
9
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 11
  • Phase 21
  • Phase 310
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy · Hemolytic Disease of the Fetus and Newborn · Lupus Erythematosus, Systemic
Next primary completion
14 May 2027 · estimated
Open drug

Icotrokinra

icotyde

10
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 310
  • Phase 40
  • Phase not recorded0
Studied condition
Arthritis, Psoriatic · Colitis, Ulcerative · Crohn Disease
Next primary completion
10 February 2027 · estimated
Open drug

Apalutamide

erleada

9
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 21
  • Phase 36
  • Phase 40
  • Phase not recorded0
Studied condition
Metastatic Castrate-sensitive Prostate Cancer · Prostate Cancer · Prostatic Neoplasms
Next primary completion
01 December 2026 · estimated
Open drug

Ramantamig

Canonical investigational asset

8
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 22
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Immunoglobulin Light-chain Amyloidosis · Multiple Myeloma · Previously Treated Amyloid Light-chain (AL) Amyloidosis
Next primary completion
14 June 2027 · estimated
Open drug

176 of 266 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 176 of 266 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Johnson & Johnson trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
READY-AD
JNJ-95597528

NCT07230860

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

  • status flip · Recorded 2026-08-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
  • enrollment change · Recorded 2026-08-01 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

Start: 20 Jan 2026 · actual
Primary completion: 19 Nov 2026 · estimated
Study completion: 10 Feb 2028 · estimated

2021202220232024202520262027202820292030
PROTEUS
Apalutamide

NCT03767244

Phase 3 · Active, not recruiting

Trial source and qualifications

A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

Start clipped at the display horizon.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 11 Jun 2019 · actual
    Primary completion: 01 Dec 2026 · estimated
    Study completion: 13 Oct 2028 · estimated

    2021202220232024202520262027202820292030
    LIBREXIA-AF
    Milvexian

    NCT05757869

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

    5 candidate observations · 1 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    4 inspected observations omitted. At most three verified observations are shown, not full history.

    • pc date moved · Recorded 2026-08-29 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

    Start: 11 Apr 2023 · actual
    Primary completion: 08 Dec 2026 · estimated
    Study completion: 08 Dec 2026 · estimated

    2021202220232024202520262027202820292030
    Reτain
    JNJ-64042056

    NCT06544616

    Phase 2 · Active, not recruiting

    Trial source and qualifications

    A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 22 Jul 2024 · actual
      Primary completion: 22 Dec 2026 · estimated
      Study completion: 05 Jan 2027 · estimated

      2021202220232024202520262027202820292030
      SunRISe-2
      Cetrelimab

      NCT04658862

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

      Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      Start clipped at the display horizon.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 07 Dec 2020 · actual
        Primary completion: 30 Dec 2026 · estimated
        Study completion: 31 Dec 2028 · estimated

        2021202220232024202520262027202820292030
        Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
        Seltorexant

        NCT06559306

        Phase 3 · Recruiting

        Trial source and qualifications

        Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        0 candidate observations · 0 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        No eligible observations recorded in the inspected period.

          Start: 25 Jul 2024 · actual
          Primary completion: 30 Dec 2026 · estimated
          Study completion: 15 Dec 2027 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 82 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 47 actual primary completions, 0 untyped primary completions, 3 past estimates, 8 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          122

          active trials in Oncology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Oncology122 trials
          • Immunology & Inflammation29 trials
          • Cardiovascular25 trials
          • Psychiatry & Addiction15 trials
          • Pain & Musculoskeletal13 trials
          • Dermatology11 trials
          • Neurology8 trials
          • Haematology5 trials
          • Respiratory4 trials
          • Ophthalmology3 trials
          • Unmapped30 trials
          • Healthy volunteers1 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 3,323 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Johnson & Johnson. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          3,323 distinct registry candidates produced 3,323 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 77 unverified, 1 identity-only and 469 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          2,940 scoped records have indexed enrichment and 383 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-11-01T00:39:36.198Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 5a62a13595d2bafba19cedf5618d62e4bb786bb664217cc686aeefafc2633fb6.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 3,323 mapped lead-sponsored clinical studies across all statuses. 2,940 have indexed enrichment, 383 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.